When did VITEK 2 AST-Yeast Anidulafungin ( = 8 µg/mL) receive FDA 510(k) clearance?

VITEK 2 AST-Yeast Anidulafungin ( = 8 µg/mL) received FDA 510(k) clearance on 2024-06-07, under 510(k) number K232963.

FDA 510(k)

VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)

K-Nummer: K232963 · 2024-06-07

AntragstellerbioMerieux, Inc.

Entscheidungsdatum2024-06-07

ProduktcodeNGZ

BeratungsausschussMI

EntscheidungSubstantially Equivalent

Produktübersicht

VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) is the device name listed in this FDA 510(k) record. The listed applicant is bioMerieux, Inc.. It received FDA 510(k) clearance on 2024-06-07 under 510(k) number K232963. The device is classified under product code NGZ. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Häufig gestellte Fragen

What is the VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)?

VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) is a medical device that received FDA 510(k) clearance on 2024-06-07. The listed applicant is bioMerieux, Inc.. The 510(k) number is K232963.

When did VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) receive FDA 510(k) clearance?

VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) received FDA 510(k) clearance on 2024-06-07, under 510(k) number K232963.

Who is the listed applicant for VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)?

The FDA 510(k) record lists bioMerieux, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)?

The FDA product code for VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) is NGZ.

Zugehörige klinische Studien

Zugehörige Einträge werden automatisch anhand von Namen, Produktcodes oder anderen Metadaten abgeglichen. Eine Übereinstimmung begründet kein verifiziertes klinisches, wissenschaftliches, unternehmerisches oder regulatorisches Verhältnis; prüfen Sie die verlinkten offiziellen Quellen.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITING NCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITING NCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED NCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Weitere Einträge mit bioMerieux, Inc. als Antragsteller

K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST System K260282VITEK 2 AST-Streptococcus Inducible Clindamycin Resistance K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)K234012VITEK COMPACT PRO K232967VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)K240279VIDAS TBI (GFAP, UCH-L1)

Alle 65 Geräte anzeigen →

Verwandte Geräte (Code: NGZ)

K243738The Sensititre YeastOne Susceptibility System with Micafungin in the dilution range of 0.008-16 µg/mLThermo Fisher Scientific K232967VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)bioMerieux, Inc.K231433The Sensititre YeastOne Susceptibility System with Rezafungin in the dilution range of 0.008-8ug/mLThermo Fisher Scientific K221198Sensititre YeastOne Susceptibility System with Fluconazole in the dilution range of 0.12-128ug/mLThermo Fisher Scientific K221899The Sensititre YeastOne Susceptibility System with Caspofungin in the dilution range of 0.015-16ug/mlThermo Fisher Scientific K211539Sensititre YeastOne Susceptibility System with Voriconazole in the dilution range of 0.008 - 8 ug/mLThermo Fisher Scientific

Offizielle Quelle

In der FDA-Datenbank anzeigen →

Daten aus der FDA Open API. Für die aktuellsten und verbindlichen Informationen konsultieren Sie bitte stets den offiziellen Datensatz.